Tensinumab (ATN-E11)
Breast Cancer (initial focus), Cancer
Pre-clinicalActive
Key Facts
Indication
Breast Cancer (initial focus), Cancer
Phase
Pre-clinical
Status
Active
Company
About aTen Therapeutics
aTen Therapeutics is a UK-based, private biotech developing antibody therapies targeting a key biological pathway in cancer. The company is in the preclinical stage with its lead asset, Tensinumab (ATN-E11), which has demonstrated tumor growth inhibition in experimental models. In August 2022, it secured a £282k Innovate UK grant to advance its breast cancer program. Led by CEO Ian Abercrombie, the company is pre-revenue and building its foundational technology platform.
View full company profile